Cytokinetics Stock Performance
| CYTK Stock | USD 61.43 0.79 1.27% |
The firm shows a Beta (market volatility) of 0.6, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cytokinetics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cytokinetics is expected to be smaller as well. At this point, Cytokinetics has a negative expected return of -0.0154%. Please make sure to confirm Cytokinetics' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Cytokinetics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Cytokinetics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Cytokinetics is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors. ...more
Actual Historical Performance (%)
One Day Return (1.27) | Five Day Return (9.82) | Year To Date Return (0.49) | Ten Year Return 837.86 | All Time Return (36.41) |
Last Split Factor 1:6 | Last Split Date 2013-06-25 |
1 | Cytokinetics Announces FDA Approval of MYQORZO for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capaci... | 12/19/2025 |
2 | Acquisition by Robert Blum of 16506 shares of Cytokinetics at 6.67 subject to Rule 16b-3 | 12/23/2025 |
3 | Disposition of 1809 shares by Andrew Callos of Cytokinetics at 62.44 subject to Rule 16b-3 | 12/29/2025 |
4 | Imbria Pharmaceuticals Announces Publication of IMPROVE-DiCE Phase 2a Data in Circulation, Demonstrating Ninerafaxstat as a Potential First-in-Class Therapy Tar... | 01/07/2026 |
5 | Disposition of 885 shares by Andrew Callos of Cytokinetics at 37.63 subject to Rule 16b-3 | 01/16/2026 |
6 | How MYQORZOs REMSRestricted U.S. Launch Will Impact Cytokinetics Investors | 01/27/2026 |
7 | Disposition of 886 shares by Andrew Callos of Cytokinetics at 37.63 subject to Rule 16b-3 | 02/02/2026 |
8 | Bayers Asundexian Shows 26 percent Stroke Reduction in Late-Stage Study | 02/06/2026 |
9 | Heart Failure Drugs Market Size to be Valued at USD 28.29 Billion by 2033 Due to the Demographic and Epidemiological Trends Globally | 02/09/2026 |
10 | Royalty Pharma Q4 2025 Earnings Transcript | 02/11/2026 |
11 | Cytokinetics to Announce Fourth Quarter Results on February 24, 2026 | 02/12/2026 |
12 | Cytokinetics, Incorporated Given Average Rating of Moderate Buy by Analysts | 02/13/2026 |
13 | Can BMYs Growth Portfolio Counter Legacy Drugs Decline in 2026 | 02/17/2026 |
14 | Truist Notes Operational Investments For Cytokinetics, Incorporated to Support Short-Term Growth | 02/18/2026 |
15 | Cytokinetics Gains EU MYQORZO Approval As Market Weighs Valuation Upside | 02/19/2026 |
| Begin Period Cash Flow | 95.2 M | |
| Total Cashflows From Investing Activities | 16.7 M |
Cytokinetics | Build AI portfolio with Cytokinetics Stock |
Cytokinetics Relative Risk vs. Return Landscape
If you would invest 6,351 in Cytokinetics on December 2, 2025 and sell it today you would lose (205.00) from holding Cytokinetics or give up 3.23% of portfolio value over 90 days. Cytokinetics is currently does not generate positive expected returns and assumes 2.7425% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Cytokinetics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cytokinetics Target Price Odds to finish over Current Price
The tendency of Cytokinetics Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 61.43 | 90 days | 61.43 | about 88.7 |
Based on a normal probability distribution, the odds of Cytokinetics to move above the current price in 90 days from now is about 88.7 (This Cytokinetics probability density function shows the probability of Cytokinetics Stock to fall within a particular range of prices over 90 days) .
Cytokinetics Price Density |
| Price |
Predictive Modules for Cytokinetics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cytokinetics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cytokinetics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cytokinetics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cytokinetics is not an exception. The market had few large corrections towards the Cytokinetics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cytokinetics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cytokinetics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.15 | |
β | Beta against Dow Jones | 0.60 | |
σ | Overall volatility | 2.23 | |
Ir | Information ratio | -0.07 |
Cytokinetics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cytokinetics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cytokinetics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cytokinetics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 88.04 M. Net Loss for the year was (784.96 M) with loss before overhead, payroll, taxes, and interest of (327.99 M). | |
| Cytokinetics currently holds about 586.03 M in cash with (510.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Cytokinetics Gains EU MYQORZO Approval As Market Weighs Valuation Upside |
Cytokinetics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cytokinetics Stock often depends not only on the future outlook of the current and potential Cytokinetics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cytokinetics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 120.1 M | |
| Cash And Short Term Investments | 882.2 M |
Cytokinetics Fundamentals Growth
Cytokinetics Stock prices reflect investors' perceptions of the future prospects and financial health of Cytokinetics, and Cytokinetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cytokinetics Stock performance.
| Return On Equity | -5.72 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (10.05) % | ||||
| Current Valuation | 7.75 B | ||||
| Shares Outstanding | 122.26 M | ||||
| Price To Earning | (37.76) X | ||||
| Price To Book | 60.31 X | ||||
| Price To Sales | 85.31 X | ||||
| Revenue | 88.04 M | ||||
| Gross Profit | (327.99 M) | ||||
| EBITDA | (775.27 M) | ||||
| Net Income | (784.96 M) | ||||
| Cash And Equivalents | 586.03 M | ||||
| Cash Per Share | 6.22 X | ||||
| Total Debt | 1.28 B | ||||
| Debt To Equity | 2.93 % | ||||
| Current Ratio | 9.01 X | ||||
| Book Value Per Share | (5.37) X | ||||
| Cash Flow From Operations | (510.01 M) | ||||
| Earnings Per Share | (6.30) X | ||||
| Market Capitalization | 7.51 B | ||||
| Total Asset | 1.42 B | ||||
| Retained Earnings | (3.49 B) | ||||
| Working Capital | 928.27 M | ||||
| Current Asset | 113.11 M | ||||
| Current Liabilities | 31.65 M | ||||
About Cytokinetics Performance
By examining Cytokinetics' fundamental ratios, stakeholders can obtain critical insights into Cytokinetics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Cytokinetics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (25.01) | (26.26) | |
| Return On Tangible Assets | (0.55) | (0.58) | |
| Return On Capital Employed | (0.50) | (0.53) | |
| Return On Assets | (0.55) | (0.58) | |
| Return On Equity | 1.19 | 1.25 |
Things to note about Cytokinetics performance evaluation
Checking the ongoing alerts about Cytokinetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cytokinetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cytokinetics generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 88.04 M. Net Loss for the year was (784.96 M) with loss before overhead, payroll, taxes, and interest of (327.99 M). | |
| Cytokinetics currently holds about 586.03 M in cash with (510.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Cytokinetics Gains EU MYQORZO Approval As Market Weighs Valuation Upside |
- Analyzing Cytokinetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cytokinetics' stock is overvalued or undervalued compared to its peers.
- Examining Cytokinetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cytokinetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cytokinetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cytokinetics' stock. These opinions can provide insight into Cytokinetics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. Projected growth potential of Cytokinetics fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Cytokinetics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (6.30) | Revenue Per Share | Quarterly Revenue Growth 0.049 | Return On Assets | Return On Equity |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Cytokinetics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cytokinetics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cytokinetics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.